Ratings Genmab A/S Nasdaq

Equities

GMAB

US3723032062

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-20 EDT			5-day change	1st Jan Change
29.69 ^USD	-0.97%		+1.82%	-6.75%

05-15	Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'	MT
05-15	Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company benefits from high valuations in earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
GENMAB A/S	-6.75%	19.21B	-
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B	B+
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B	B+
ARGENX SE	-2.59%	21.96B	B
BIONTECH SE	-12.38%	21.87B	B+
BEIGENE, LTD.	-3.35%	18.08B	B
WUXI APPTEC CO., LTD.	-38.57%	17.71B	A-
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B	C+
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B	C+
LEGEND BIOTECH CORPORATION	-24.50%	8.23B	D

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes